Stock comparison
Nektar Therapeutics
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
NKTR
Nektar Therapeutics
Market cap
$1.33B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | NKTR | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 37D | 71B | UTHR |
| Benjamin Graham | 56D | 76B | UTHR |
| Philip Fisher | 48D | 76B | UTHR |
| Peter Lynch | 3F | 62C | UTHR |
| Joel Greenblatt | 2F | 46D | UTHR |
| Charlie Munger | 39D | 64C | UTHR |
| Terry Smith | 43D | 64C | UTHR |
Side-by-side metrics
| Metric | NKTR | UTHR |
|---|---|---|
| Market cap | $1.33B | $24.13B |
| P/E (TTM) | - | 19.2x |
| EV/EBIT | - | 15.2x |
| ROIC (TTM) | -17.17% | 18.81% |
| Gross margin | 99.38% | 86.58% |
| Net margin | -2.84% | 40.61% |
| Revenue CAGR 5y | -14.2% | 17.22% |
| EPS CAGR 5y | - | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
NKTR leads on
- EV/EBIT-vs 15.2x+173%
- P/E (TTM)-vs 19.2x+163%
- Gross margin99.38%vs 86.58%+13%
UTHR leads on
- ROIC (TTM)18.81%vs -17.17%+191%
- Revenue CAGR 5y17.22%vs -14.2%+182%
- Net margin40.61%vs -2.84%+114%
- Debt / Equity-vs 0.1x+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.